DiscoveryProbe™ FDA-approved Drug Library: Mechanism-Rich Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) by APExBIO is a curated collection of 2,320 bioactive compounds approved or listed by major regulatory agencies including the FDA, EMA, HMA, CFDA, and PMDA. The library supports high-throughput screening (HTS) and high-content screening (HCS) by providing pre-dissolved 10 mM solutions in DMSO, stable for up to 24 months at -80°C. Compounds encompass diverse mechanisms of action—agonists, antagonists, enzyme inhibitors, and ion channel modulators—enabling drug repositioning and target identification. Recent studies have leveraged this resource to disrupt protein-protein interactions in cancer models, directly linking library use to translational outcomes (He et al., 2023). The library’s compatibility with automated workflows accelerates discovery in oncology, neurodegeneration, and complex signaling pathways.

Biological Rationale

Drug repositioning capitalizes on the established safety and pharmacokinetics of clinically approved compounds. Libraries of approved drugs, such as the DiscoveryProbe™ FDA-approved Drug Library, streamline the identification of new therapeutic applications by providing well-characterized molecules with diverse molecular targets (He et al., 2023). Disease mechanisms—such as aberrant apoptosis in cancer or dysregulated signaling in neurodegenerative disorders—require precise modulation of protein networks. Targeted screening with mechanism-rich libraries enables systematic exploration of these pathways. The L1021 kit’s global regulatory coverage ensures relevance across international research contexts.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library comprises compounds acting as receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators. Representative drugs include doxorubicin (DNA intercalator), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). Each compound is annotated with known mechanisms of action, facilitating target-based and phenotypic screens. The pre-dissolved 10 mM DMSO solutions enhance reproducibility and assay compatibility. For example, recent HTS applications have identified compounds that disrupt 14-3-3:BAD protein interactions, modulating apoptosis in colorectal cancer cells under defined serum conditions (He et al., 2023).

Evidence & Benchmarks

• High-throughput screening of 1,971 FDA-approved compounds using a BRET-based assay identified multiple disruptors of 14-3-3:BAD interactions in colorectal cancer cell lines (He et al., 2023, https://doi.org/10.1101/2023.12.14.571727).
• Terfenadine, penfluridol, and lomitapide were found to induce apoptosis in HT-29 and Caco-2 cells at micromolar concentrations, validated by cell viability and caspase activity assays (He et al., 2023, https://doi.org/10.1101/2023.12.14.571727).
• The DiscoveryProbe™ FDA-approved Drug Library supports robust phenotypic screening with a Z'-score of 0.52, indicating high assay quality under typical HTS conditions (He et al., 2023, https://doi.org/10.1101/2023.12.14.571727).
• Compounds retain chemical integrity for 12 months at -20°C and 24 months at -80°C, enabling long-term projects and reproducibility (APExBIO product documentation, product page).
• Mechanistic coverage extends across oncology, neurodegeneration, infectious diseases, and metabolic disorders as cataloged in internal translational frameworks (related review).

For further reading, this article extends prior analyses by demonstrating how the L1021 kit bridges mechanistic and translational discovery, whereas this recent review focuses on the library’s role in mechanism mapping and evidence synthesis.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library enables:

• Drug repositioning screening for oncology, neurodegeneration, and immunology research.
• Pharmacological target identification via high-content cellular imaging and pathway analysis.
• Signal pathway regulation studies, including kinase, phosphatase, and ion channel modulation.
• Evaluation of compound efficacy in disease models with defined end-point assays.

For immune checkpoint blockade and translational impact in complex disease models, see this article, which is complemented here with new evidence on apoptosis-inducing screens in cancer.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for in vivo studies without revalidation of formulation and dosing.
• The library does not guarantee hit-to-lead translation; clinical context and secondary validation are required.
• Some compounds may display off-target effects unrelated to their annotated mechanism in specific cell types.
• Compounds are dissolved in DMSO; care must be taken to control for solvent effects at higher concentrations.
• The resource is designed for discovery, not for direct clinical use.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is supplied in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes. Compounds are provided as 10 mM solutions in DMSO. Shipping is performed on blue ice for evaluation samples, and at room temperature or on blue ice (upon request) for larger quantities. Solutions are stable for 12 months at -20°C and up to 24 months at -80°C (product documentation). The format supports automated liquid handling and integration into robotic HTS/HCS pipelines. Standard screening concentrations range from 1–50 μM, depending on assay sensitivity and cell/tissue context. Data analysis pipelines incorporate hit validation, secondary screening, and mechanistic annotation. The L1021 kit’s format ensures rapid assay setup and minimal preparation time, reducing variability. For further workflow and reproducibility discussions, see this detailed overview, which is updated here with the latest stability and shipping parameters.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library by APExBIO provides a validated, mechanism-diverse compound collection for accelerating drug repositioning and pharmacological target identification. Its assay-ready, pre-dissolved format and global regulatory coverage make it a cornerstone resource for translational research. Recent applications demonstrate the feasibility of identifying novel apoptosis-inducing agents in cancer models, underscoring the library’s value in both mechanistic and phenotypic discovery screens. Future directions include expanded annotation of compound-target interactions and broader disease modeling applications. For ordering and technical details, visit the DiscoveryProbe™ FDA-approved Drug Library product page.